Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.58 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.58 |
| ▸ | MYC | P01106 | 1/20 | 0.56 |
| ▸ | MAX | P61244 | 1/20 | 0.56 |
| ▸ | CASP6 | P55212 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.53 |
| ▸ | HCAR3 | P49019 | 8/20 | 0.52 |
| ▸ | EP300 | Q09472 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL223553 | 0.93 | AKR1C3 (0.67) | AKR1C3AKR1C2AKR1C1MYCMAX | |
| SCHEMBL7833539 | 0.92 | PLA2G4B (0.63) | AKR1C3AKR1C2AKR1C1MYCMAX | |
| SCHEMBL177201 | 0.89 | PLA2G4B (0.65) | CASP6TSHRPLA2G4BHCAR3MAPT | |
| SCHEMBL3537490 | 0.88 | MAPT (0.62) | AKR1C3AKR1C2AKR1C1MYCMAX | |
| SCHEMBL22660910 | 0.87 | AKR1C3 (0.52) | AKR1C3AKR1C2AKR1C1MYCMAX | |
| Hydrochloric Acid SCHEMBL3729179 | 0.87 | MAPT (0.60) | AKR1C3AKR1C2AKR1C1MYCMAX | |
| SCHEMBL11949145 | 0.86 | AR (0.58) | AKR1C3AKR1C2AKR1C1MYCMAX | |
| SCHEMBL3109614 | 0.84 | AKR1C3 (0.57) | AKR1C3AKR1C2AKR1C1MYCMAX | |
| SCHEMBL6707224 | 0.84 | MYC (0.55) | AKR1C3AKR1C2AKR1C1MYCMAX | |
| SCHEMBL7824920 | 0.83 | AKR1C3 (0.57) | AKR1C3AKR1C2AKR1C1MYCMAX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144741-A1 | ETHANOLAMINE DERIVATIVES USEFUL AS BACE INHIBITORS | FREDERIKSEN MATHIAS | 2010-06-10 | — | — | US | disclosed |
| EP-2094645-A1 | 2-HYDROXY-1,3-DIAMINOPROPANE DERIVATIVES | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008062044-A1 | 2-HYDROXY-1,3-DIAMINOPROPANE DERIVATIVES | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144741-A1 | ETHANOLAMINE DERIVATIVES USEFUL AS BACE INHIBITORS | BACE1, BACE2, APP | AKR1C3 1147/4885AKR1C2 935/4885AKR1C1 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.